



**SERES**  
THERAPEUTICS™

## Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

January 4, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2018-- [Seres Therapeutics, Inc.](#) (NASDAQ:MCRB) today announced that it will present at the 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 11 at 8:30 a.m. PT.

A live audio webcast of the presentation and breakout question and answer session will be available under the "Investors and Media" section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

### About Seres Therapeutics

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres' lead program, SER-109, has obtained Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent *C. difficile* infection. Seres' clinical candidate SER-287 has successfully completed a Phase 1b study in patients with mild-to-moderate Ulcerative Colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary *C. difficile* infection. For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com). Follow us on Twitter @SeresTx.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20180104005392/en/>

Source: Seres Therapeutics, Inc.

### IR or PR Contact:

Seres Therapeutics  
Carlo Tanzi, Ph.D., 617-203-3467  
Head of Investor Relations and Corporate Communications  
[ctanzi@serestherapeutics.com](mailto:ctanzi@serestherapeutics.com)